NewTimeSpace News: Manulife Financial reports Q2 2026 core earnings of CAD 1.9 billion (+12% YoY) and shareholder net income of CAD 2.1 billion; core EPS rose 16% to CAD 1.09 with core ROE at 16.3%; APE sales up 21% and new business value up 10%; Asia core earnings grew 21%, U.S. up 55%, Canada down 10%; returned CAD 2.6 billion to shareholders in 1H 2026.
NewTimeSpace News: Eastroc Beverage announces subsidiaries subscribed for RMB 550 million wealth management products from Huaxia Bank with expected yields of 2.12%-2.15%; combined with previous RMB 1,857 million subscriptions, the total constitutes a notifiable transaction under Chapter 14; funded by idle capital without affecting working capital.
NewTimeSpace News: Nanjing Leads Biolabs announces WeilixinTM Phase II study for first-line HCC enters expansion stage; preliminary data shows positive efficacy and good safety in combination with bevacizumab; the drug has initiated 13 solid tumor indications in China and is the world's first 4-1BB-targeting molecule in pivotal registration trials.
NewTimeSpace News: China Chunlai Education proposes acquiring Dublin Business School for USD 127.5 million; target serves approximately 9,000 students annually with 2025 revenue of EUR 49.8 million; Irish authorities confirmed no review required; major transaction subject to shareholder approval via written consent.
NewTimeSpace News: Wai Chun Bio-Technology signs exclusive overseas general agency agreement with Henan Mine Crane for global markets excluding mainland China; three-year term with renewal rights; licensor is a leading Chinese crane manufacturer with annual revenue of approximately RMB 6.5 billion; company adopts a light-asset model with autonomous pricing to capture global infrastructure demand.
August 05, 2026, BEONE MEDICINES(06160.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 3.22 billion, increased by 32.31% YoY
CHINAHEALTHWISE (00348.HK) plans to issue in total 154.09 million shares.
NewTimeSpace News: AOM INT'L(00381.HK) announced that due to failure to reach further consensus on key terms, the Company and Yalu Cloud have agreed to terminate the previously‑signed strategic cooperation agreement on 5 August 2026. No binding formal agreement has been concluded. The Board holds the view that the termination will not result in any material adverse impact on the Group’s current operations and financial position.
NewTimeSpace News: Lygend Resource (02245.HK) announced on 5 August that the Phase‑II KPS Project (12 production lines, annual capacity of 185,000 metal tons of ferronickel) of the RKEF facility on Indonesia’s Obi Island has achieved full production. The Obi project now delivers a combined annual capacity of 400,000 metal tons of nickel. The Company expects to unlock scale benefits and improve profitability.
NewTimeSpace News: Boan Biotech (06955.HK) announced on 5 August that the marketing authorization application for aflibercept biosimilar BA9101 has been filed in Brazil for wet AMD and diabetic macular edema. EYLEA recorded global sales of USD5.321 billion in 2025 and Brazil’s pharmaceutical market reached USD39 billion. Having obtained approval in China, the product is accelerating its overseas expansion.
NewTimeSpace News: Luye Pharma (02186.HK) announced that self‑developed new molecular entity LY03015, the world’s first VMAT2 inhibitor and Sigma‑1R agonist, has successfully completed a bridging clinical trial in the United States, supporting the upcoming efficacy‑oriented clinical trial in the US. Previous Phase II clinical data from China showed that the AIMS response rate reached 76.5% in the 20mg dose group, exceeding historical therapeutic benchmarks.
NewTimeSpace News: The Shanghai Stock Exchange announced adjustments to the list of eligible Southbound stocks under the Shanghai-Hong Kong Stock Connect pursuant to the SSE's implementation rules. MINIMAX-W, LUXSHARE-ICT, and CCTC have been added, effective from the next Southbound trading day. All three are industry leaders in their respective segments, spanning general artificial intelligence, precision intelligent manufacturing, and advanced materials.
NewTimeSpace News:VICO INTL HLDGS(01621.HK) announced that Ms. Wu Yingsi has resigned as Independent Non‑executive Director and member of the Audit Committee, Remuneration Committee and Nomination Committee with effect from 5 August 2026 due to personal matters and work arrangements. Following her resignation, the Company fails to comply with several Listing Rules requirements concerning the minimum number of Independent Non‑executive Directors (at least three), minimum size of the Audit Committee (at least three), composition of the Remuneration Committee and gender diversity of the Nomination Committee.
NewTimeSpace News: Everest Gold (01815.HK) announced the latest exploration progress at Shannan Mine and Shigatse Mine. A roughly east‑west trending mineralised zone has been preliminarily delineated in the Gudui Area of Shannan Mine, with a strike length of around 1,000 metres and a down‑dip extent of approximately 500 metres. Preliminary assay of grab samples indicates gold mineralisation, with associated antimony and cobalt mineralisation encountered in some sections. Skarn‑type polymetallic mineralisation and molybdenum mineralisation outcrops have been identified in the Xiaqiu Area of Shigatse Mine.
NewTimeSpace News: Realord Tech (01196.HK) announced that 9,218,000 shares beneficially owned by Meilin Holdings, held by executive director Dr. Lin Xiaohui and Ms. Su Jiaohua, were sold on the market on 30 July 2026 through forced sale. The shares account for approximately 0.64% of issued shares. The sale took place within the black‑out period prior to the release of interim results. Nonetheless, the Directors hold the view that the sale falls within the definition of special circumstances under the Listing Rules.
NewTimeSpace News: Remegen (09995.HK) released its interim performance forecast. The Company expects operating revenue of approximately RMB5.85 billion for H1 2026, representing a YoY increase of 433%. Net profit attributable to owners of the parent is projected at about RMB4.7 billion, marking a return to profitability (compared with a loss of approximately RMB450 million in the same period last year). Domestic sales of core products telitacicept and disitamab vedotin kept growing, coupled with a substantial rise in technology licensing income generated from the exclusive licensing agreement for RC148 with AbbVie.
